CLIA-Validated PBMC Mass Cytometry Immune Profiling Assay
Clinical trials-grade immunophenotyping with 40+ markers for peripheral blood immune detection
Identify immune biomarkers for dose selection, mechanism of action, and pharmacodynamic studies in your clinical trials.
Analyze up to 840 immune cell subsets and states with our 41-marker mass cytometry panel. Accurate subset measurements with <10% coefficient of variation for all major immune cell types.
Total Average Coefficient of Variations:
- Intra-Run Precision: 3.52%
- Inter-Run Precision: 6.66%
- Inter-Operator Precision:
- Donor 1: 4.83%
- Donor 2: 7.36%
Validated with cryopreserved human PBMC.
Up to 800+ Immune Subsets and States Analyzed
Expertly Designed Human Pan-Immune PBMC Panel
The TokuProfile Standard Human Pan-Immune PBMC panel includes:
- Markers to identify every major immune cell population and subsets.
- Expression of key co-stimulatory and co-inhibitory molecules that regulate cell function.
- Markers of recent activation and effector function.
Markers to define cell populations and quantify functional states
Coefficient of Variation (CV) Among Immune Cell Subsets
Precision and Median Cell Count Data
* = No CV calculated (subset was below 100-cell minimum in >1 replicate)
CLIA Validation Data
Mass Cytometry Assay for Pan-Immune Profiling of PBMCsFill out the form below to access our CLIA Validation plan, report, and data and SOPs.